Pharmacopoeia-based medicaments, SSI exemption, and export turnover exclusion shaped excise duty treatment and limitation analysis.

The note states that medicinal products manufactured in accordance with the pharmacopoeia, where alcohol is required in the formulation, are excluded from central excise duty under Chapter Note 5 of Chapter 30 even if the label does not mention alcohol content. It further explains that oral capsules falling within the small scale industry framework remained eligible for exemption because turnover, after the Section 4A abatement, stayed below the threshold and export turnover was not to be included in the limit. On limitation, it records that a bona fide classification dispute and absence of wilful suppression prevented invocation of the extended period.

---

---

Issues: (i) whether Category C and D medicines were outside the levy of central excise duty as medicaments containing alcohol under Chapter Note 5 of Chapter 30; (ii) whether Category E oral capsules were eligible for small scale industry exemption and whether export turnover could be excluded while computing the turnover limit; (iii) whether the demand for the extended period was barred by limitation for want of wilful suppression.

Issue (i): whether Category C and D medicines were outside the levy of central excise duty as medicaments containing alcohol under Chapter Note 5 of Chapter 30.

Analysis: The pharmacopoeia entries showed that alcohol was required in the preparation of the Category C and D products, even though the outer labels did not expressly mention alcohol content. Chapter Note 5 of Chapter 30 does not prescribe any minimum percentage of alcohol and does not require the alcohol content to be stated on the label. The decisive factor is whether alcohol is used in accordance with the pharmacopoeia in the manufacture of the medicaments.

Conclusion: The Category C and D goods fell outside the purview of excise duty and the confirmed demand on these goods was unsustainable.

Issue (ii): whether Category E oral capsules were eligible for small scale industry exemption and whether export turnover could be excluded while computing the turnover limit.

Analysis: The Category E goods were dutiable in principle, but the turnover, after the 35% abatement on MRP basis under Section 4A, remained below the threshold of Rs. 1.50 crores for each disputed year. The turnover certificate, supported by the audited accounts, and the VAT assessment materials showed substantial exports. Export turnover was not liable to be included for computing the exemption limit under Notification No. 08/2003-CE.

Conclusion: The appellant was entitled to the small scale industry exemption and no excise duty was payable on Category E goods.

Issue (iii): whether the demand for the extended period was barred by limitation for want of wilful suppression.

Analysis: The record showed a bona fide dispute on classification and duty liability, and the export turnover position was found to be correct. In the circumstances, the Department failed to establish wilful suppression with intent to evade duty.

Conclusion: Invocation of the extended period was not justified and the demand was barred by limitation.

Final Conclusion: The confirmed demands were set aside on merits as well as on limitation, and the appellant obtained consequential relief according to law.

Ratio Decidendi: Where a medicinal product is manufactured in accordance with the pharmacopoeia requiring alcohol use, Chapter Note 5 to Chapter 30 excludes it from excise duty even if the label does not state alcohol content; and for SSI exemption, export turnover is excluded while computing the eligibility threshold, absent proof of wilful suppression.

---